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Abstract
When combining osteogenic progenitor cells such as human 
periosteum derived cells (hPDCs) with osteoconductive 
biomaterials like calcium phosphate (CaP)-scaffolds, in 
vivo bone formation can be achieved. This process is 
dependent on the early activation of Bone morphogenetic 
protein (BMP)-signalling. However, the bone forming 
process is slow and routinely only a limited amount of bone 
and bone marrow is formed. Therefore, we hypothesised 
that a robust clinically relevant outcome could be achieved 
by adding more physiological levels of potent BMP-ligands 
to these cell- and CaP-based constructs.
 For this, hPDCs were characterised for their 
responsiveness to BMP-ligands upon in vitro 2D 
stimulation. BMP-2, -4, -6 and -9 robustly induced 
osteochondrogenic differentiation. Subsequently, these 
ligands were coated onto clinically approved CaP-scaffolds, 
BioOss® and CopiOs®, followed by hPDC-seeding. Protein 
lysates and conditioned media were investigated for 
activation of BMP signalling pathways. Upon in vivo 
implantation, the most abundant bone formation was found 
in BMP-2 and BMP-6-coated scaffolds. Implanted cells 
actively contributed to the newly formed bone. Remnants 
of cartilage could be observed in BMP-coated CopiOs®-
constructs.
 Computational analysis displayed that the type of BMP-
ligand as well as the CaP-scaffold affects skeletal tissue 
formation, observed in a qualitative as well as quantitative 
manner. Furthermore, the in vitro mechanism appears to 
predict the in vivo outcome. This study presents further 
evidence for the potential of BMP-technology in the 
development of clinically relevant cell-based constructs 
for bone regenerative strategies.
Keywords: bone tissue engineering, bone morphogenetic 
proteins, calcium phosphate, progenitor cell, cell 
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Introduction
Over 10 % of annual tibia fractures lead to non-unions, 
often due to the critical size of the fracture, severely 
damaged surrounding tissue and/or genetic disorders (Fong 
et al., 2013). Unfortunately, the gold standard methods to 
treat non-unions today, autograft or allograft transplants, 
arouse inevitable limitations such as donor site morbidity 
and the risk of allogeneic contaminations (Betz, 2002). 
Subsequently, bone tissue engineering (BTE) has in the last 
decades emerged as a promising approach of alternative 
treatments and specifically of cell-based Advanced Therapy 
Medicinal Products (ATMPs) (Langer and Vacanti, 1993; 
Ma et al., 2014). The classical elements in this strategy 
contain osteoprogenitor cells seeded on an osteoconductive 
3D material which, when combined with osteoinductive 
biomolecules, forms a BTE-ATMP.
 For a successful outcome, a biomimetic approach 
such as developmental engineering should be utilised 
(Lenas et al., 2009a). In view of this, human periosteum 
derived cells (hPDCs) are particularly of interest, due to 
their in vivo bone forming capacity and direct contribution 
in fracture healing (Colnot, 2009; Roberts et al., 2015). 
In constructs based on hPDC-seeded calcium phosphate 
(CaP)-scaffolds, Ca2+ was found as an essential determinant 
for the constructs’ bone forming capacity (Roberts et al., 
2011). Furthermore, it was shown that activation of the 
Bone morphogenetic protein (BMP) and Wingless-related 
(Wnt) signalling was crucial for the osteogenic capacity of 
the construct (Eyckmans et al., 2010). This is of specific 
interest since these pathways reflect the key growth factors 
during limb formation as well as normal fracture healing 
where they recruit/trigger periosteal cells to aid the fracture 
healing (Ai-Aql et al., 2008; Barnes et al., 1999; Cho et 
al., 2002; Yu et al., 2010). Nevertheless, bone formation in 
these constructs is a slow process and only limited amount 
of bone and marrow formation have been obtained until 
today. To improve the bone forming capacity of these 
CaP/cell-based constructs further, a potential biomimetic 
strategy could be to coat the scaffolds with osteoinductive 
factors such as BMPs prior to cell seeding.
 In the clinical setting, BMP-2 and BMP-7 have been 
approved, but due to the design of these medicinal products, 
supra-physiological levels of BMPs are required, leading 
to side effects (Glassman et al., 2007; Graham et al., 2014; 
Pobloth et al., 2015; Tiedemann et al., 2001; Varga and 
Wrana, 2005; White et al., 2007; Wu and Hill, 2009). When 
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inducing physiological cellular responses, BMP-ligands 
activate intracellular signalling by binding to their cognate 
transmembrane receptors. The active receptor complex 
resides on one of the type1 receptors: Activin Receptor-
like Kinase (ALK)1, ALK2, ALK3 or ALK6 and one 
of the type2 receptors: BMP-receptor type 2 (BMPR2), 
Activin type 2 receptor (ACVR2)a or ACVR2b (Shimasaki 
et al., 2004). BMP ligands bind to their receptors with 
different affinities depending on cell type, cellular state 
and environment, whereas the oligomerisation mechanism 
determines downstream signalling activation (Gilboa et al., 
2000; Hartung et al., 2006; Nohe et al., 2002). Even though 
research progressively unravels the complex intracellular 
system of BMP-signalling, limited information is available 
regarding the biological performance of the different 
BMPs on clinically relevant progenitor cells such as 
hPDCs. In addition, in the perspective of BTE-strategies 
for clinical translation, it is of relevance to know how 
a 3D CaP-environment affects the cellular response to 
more physiological levels of BMP-ligands and how this 
is reflected in the in vivo situation.
 In view of this, the current study aimed to evaluate the 
biological performance of ATMPs constituted of BMPs 
and CaP-scaffolds as osteoinductive and -conductive raw 
materials and hPDCs as osteoprogenitor cells. Initially, 
hPDCs were characterised in terms of their responsiveness 
to different BMP-ligands. The most potent members were 
selected for coating onto two clinically used CaP scaffolds: 
BioOss® and CopiOs®, with previously reported limited 
and no bone forming capacity in combination with hPDCS, 
respectively (Roberts et al., 2011). Activated signalling 
pathways were analysed in vitro and the skeletal tissue 
forming capacity of the cell-based BMP-CaP constructs 
was investigated in vivo. As a last step, computational 




Expansion of human periosteum-derived cells (hPDCs)
Isolation and in vitro expansion of hPDCs were carried out 
as previously described (De Bari et al., 2001). Expanded 
cells from six different donors (age 14.9 ± 2.1) were pooled 
as a representative sample and in vitro expanded in growth 
medium (GM) consisting of high-glucose Dulbecco`s 
modified medium (DMEM, Invitrogen, Merelbeke, BE) 
supplemented with 10 % foetal bovine serum (FBS) 
(Gibco, Merelbeke, BE), sodium pyruvate and antibiotics-
antimycotics solution (Invitrogen). Upon confluence, 
hPDCs were trypsin-released (1 mM EDTA; Invitrogen) 
and re-plated with a seeding density of 5000 cells/cm2 
and used accordingly at passage 5. The ethical committee 
for human medical research (KU Leuven) approved 
all procedures, and the patient informed consents were 
obtained.
Mesenchymal stem cell markers and hPDCs
Prior to the in vitro evaluation, flow cytometry was 
performed to characterise the expression of mesenchymal 
stem cell (MSC) markers on hPDCs by using a human MSC 
phenotyping kit (130-095-198, Miltenyi Biotec, Leiden, 
NL). The extracellular staining was performed according to 
the manufacturer’s instruction. In brief, the cell suspension 
was mixed with MSC Phenotyping Cocktail and incubated 
in dark at 4 °C. Cells were washed and analysed using BD 
FACS Canto™ cell analyser (BD Biosciences, San Jose, 
USA) with FlowJo V10 software.
BMP receptor expression
Expression of BMP type 1 and type 2 receptors was 
investigated by mRNA transcript analysis. Total RNA 
from expanded hPDCs was extracted by lysing cells 
in RLT buffer supplemented with β-mercaptoethanol. 
Further RNA extraction was performed using the RNeasy 
kit (Qiagen, Venlo, NL) according to the manufacturer’s 
instructions. Complementary DNA (cDNA) was obtained 
by reverse transcription of total RNA with Oligo (dT)20 
as primer (Superscript III; Invitrogen). Quantitative 
PCR was performed in duplicates on a Rotor-Gene 6000 
system (Corbett, Westburg, Leusden, NL) as previously 
described (Roberts et al., 2011). Relative gene expression 
levels were calculated using the 2−ΔCT or 2−ΔΔCT method 
by normalising to the housekeeping gene hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) and non-stimulated 
control. For primer sequences see table 1. On protein 
level, expression of BMP type 1 and type 2 receptors 














Table 1. Primer sequences.
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was detected by immunohistochemistry (IHC). A human 
prostate cancer cell line (PC3) was used as a positive 
control. Cells cultured on 4-well chamber slides (Thermo 
Scientific™ Nunc™ Lab-Tek™, Breda, NL) were fixed 
and permeabilised (PBS containing 0.5 % Triton-X and 
10 % FBS) before antibody incubation. Next, cells were 
incubated overnight at 4 °C with human specific antibody 
ALK2 (AF637, R&D Systems), ALK3 (NBP2-37421, 
Novus Biologicals, Abingdon, UK), ALK6 (Mab5051, 
R&D Systems, Abington, UK) or BMPR2 (AF811, R&D 
Systems). As isotype controls, cells were stained with 
normal goat IgG (AB-108-C, R&D Systems), mouse IgG2B 
(mab0041, R&D Systems) and mouse IgG1 (ab18447, 
Abcam, Cambridge, UK). Subsequently, cells were 
stained with nucleus stain 4′-6-diamidino-2-phenylindole 
(DAPI) dye (1:2000) and donkey anti-goat IgG, Alexa 
Fluor® 488 conjugate (1:200, A21432, Life Technologies, 
Erembodegem, BE) or donkey anti-mouse IgG Alexa 
Fluor® 488 conjugate (1:200, A21202, Life Technologies). 
Samples were mounted in Mowiol (Merck, Darmstadt, DE) 
for fluorescent microscopic analysis (Leica, Diegem, BE 
and Spot Imaging Solutions™, Sterling Heights, USA).
Response of 2D cultured hPDCs to BMP-stimulation
In vitro expanded cells were seeded in monolayer cultures 
at a density of 10,000 cells/cm2 and left overnight for 
attachment. Monolayers were washed in PBS followed 
by synchronisation for 16 h in GM containing 0.1 % 
FBS. Next, cells were stimulated with GM supplemented 
with 100 ng/mL of vehicle (PBS, in order to dilute stock 
solutions), BMP-2, BMP-4, BMP-6, BMP-7, BMP-9 
or Growth differentiation factor 5 (GDF-5) (Peprotech, 
London, UK) for 6 d. Following stimulation, monolayers 
were imaged by bright field microscopy (Zeiss, Zaventem, 
BE) followed by RNA isolation. Subsequent mRNA 
analysis was performed as described in the section headed 
BMP receptor expression. Gene expression analysis for 
chondrogenic markers; sex determining region Y-box 
9 (SOX9) and aggrecan (ACAN), osteogenic markers; 
Runt-related transcription factor 2 (RUNX2), osterix 
(OSX) and osteocalcin (OCN) together with activated 
BMP-signalling; inhibitor of differentiation 1 (ID1) and 
distal-less homeobox 5 (DLX5) was performed. Primer 
sequences are defined in Table 1.
Characterisation of 3D CaP-environment
Biomaterial preparation
Two clinical grade CaP-based scaffolds with known 
bone forming capacity in combination with hPDCs, i.e.: 
limited bone formation: BioOss® (Geistlich, Princeton, 
US); and no bone formation: Copios® (Zimmer, Wemmel, 
BE) were selected based on previous work (Roberts et 
al., 2011). CopiOs® contains synthetic CaP-granules 
embedded in bovine collagen and BioOss® contains bovine 
CaP-granules embedded in porcine collagen. From each 
material cylindrical (3 mm diameter and 3 or 5 mm in 
height for BioOss® and CopiOs®, respectively) scaffolds 
were punched out.
Ca2+ release measurements from the biomaterials
The release kinetics of Ca2+ from the biomaterials 
were analysed by Inductively Coupled Plasma-Atomic 
Emission Spectrometry (ICP-AES). Briefly, scaffolds 
were submerged in Ca2+-free PBS and rotated at 37 °C. 
Samples were collected to measure the release kinetics 
after 24, 74 and 144 h. Standards were used to assess Ca2+-
concentration and blank medium was used as baseline. 
Subsequent analyses were performed by ICP-AES, using 
a Varian, Liberty Series II.
BMP-coating and cell seeding of biomaterials
Five groups of scaffolds (n = 7) loaded with the BMP-
ligands were set up for cellular response evaluation. The 
doses and resources of BMPs are listed in Table 2. Each 
scaffold was coated with 50 ng/mm3 scaffold of BMP 
ligand or vehicle and left for adsorption for 1 h at 37 °C. 
Subsequently, 50,000 hPDCs/mm3 scaffold were drop-
seeded onto coated scaffolds. Constructs were incubated 
for 24 h at 37 °C and 5 % CO2 to allow cell attachment. 
Next, medium was collected for analysis of BMP-release 
from the scaffold together with lactate and glucose 
measurements. Constructs were used for further protein 
phosphorylation analysis (n = 3) and in vivo implantation 
(n = 4).
BMP-2 release from biomaterials
The materials’ ability to retain coated growth factors was 
analysed by a human BMP-2 enzyme linked immunosorbent 
assay (ELISA) development kit (Peprotech). Conditioned 
Table 2. Conditions for 3D constructs.
Group Scaffold Scaffold manufacturer BMP-coating Dose BMP-resource
Control BioOss® BioOss® Geistlich Vehicle coated ND ND
Control CopiOs® CopiOs® Zimmer Vehicle coated ND ND
BioOss®- BMP-2 BioOss® Geistlich BMP-2 50 ng/mm3 Medtronic
CopiOs®-BMP-2 CopiOs® Zimmer BMP-2 50 ng/mm3 Medtronic
BioOss®- BMP-4 BioOss® Geistlich BMP-4 50 ng/mm3 PeproTech
CopiOs®-BMP-4 CopiOs® Zimmer BMP-4 50 ng/mm3 PeproTech
BioOss®- BMP-6 BioOss® Geistlich BMP-6 50 ng/mm3 Genera research
CopiOs®-BMP-6 CopiOs® Zimmer BMP-6 50 ng/mm3 Genera research
BioOss® -BMP-9 BioOss® Geistlich BMP-9 50 ng/mm3 PeproTech
CopiOs®-BMP-9 CopiOs® Zimmer BMP-9 50 ng/mm3 PeproTech
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media from BMP-2 coated scaffolds, non-seeded or seeded 
with hPDCS, were collected after 24 h. The ELISA was 
performed according to the manufacturer’s instructions.
Lactate and glucose measurements
The lactate and glucose concentrations in the medium 
were measured by two clinical diagnosis test strips; 
lactate ProTM test strip (ARKRAY, Europe B.V, NL) and 
Contour® blood glucose test strips (Bayer Consumer Care 
AG, CH). The measurements were performed according 
to manufacturer’s instructions. In brief, samples were 
loaded on the strip and immediately read by a Contour® 
meter (Bayer Consumer Care AG). Each sample was 
measured twice to minimise technical error. Blank medium 
was measured as control to calculate lactate production 
and glucose consumption. Thereafter, the ratio of lactate 
production to glucose consumption per cell was calculated 
to compare the metabolic activity of the cells upon seeding 
in different groups.
Downstream pathway activation by Western blot
Cell-seeded 3D materials were homogenised in Cell 
Extraction Buffer (Thermo Scientific) containing 
0.3 M Phenylmethanesulphonyl fluoride and Protease 
Inhibition Cocktail (Sigma-Aldrich, Bornem, BE). 
Protein concentration was determined using the Pierce 
BCA Protein Assay Kit (Thermo Scientific) according to 
manufacturer’s instructions. Equal quantities of protein 
were loaded on NuPAGE 4-12 % Bis-Tris gels (Invitrogen) 
and electrophoresed to separate proteins according to 
size. These proteins were subsequently transferred to a 
Polyvinylidene fluoride membrane by wet transfer for 
further analysis. Phosphorylation of Smad1/5/8, p38, 
ERK1/2 and MEK1/2 was investigated, representing 
canonical Smad-dependent as well as non-canonical Smad-
independent BMP-signalling. Primary antibodies were 
diluted according to the manufacturer`s instructions: rabbit 
monoclonal Phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204) (197G2), rabbit p44/42 MAPK (Erk1/2), rabbit 
monoclonal Phospho-p38 MAPK (Thr180/Tyr182) (12F8), 
rabbit p38 MAPK, rabbit polyclonal Phospho-Smad1 
(Ser463/465)/Smad5 (Ser463/465)/Smad8 (Ser426/428) 
(Cell Signalling Technology- BIOKÉ, Leiden, NL). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mouse monoclonal (Abcam) was used to assess equal 
loading of proteins. HRP-conjugated secondary antibodies 
were used at a dilution of 1:2000 (Jackson, Pennsylvania, 
US) and images were developed by a LAS3000 Imaging 
System (FUJI) following the application of SuperSignal® 
West Femto reagent (Thermo Scientific, Illnois, US). 
Densitometry analysis was performed using Biorad 
Quantity One software.
In vivo osteogenesis
Constructs (n = 4) (prepared as described in the section 
headed BMP-coating and cell seeding of biomaterials) 
were implanted subcutaneously in the cervical region of 
NMRInu/nu mice (Janvier, Genest Saint Isle, FR). For in 
vivo bone formation, explants were harvested 5 weeks post 
implantation, fixed in 4 % paraformaldehyde and stored 
in PBS until further analysis. For 3D quantification and 
qualitative analysis, explants were scanned by nanofocus 
X-ray computed tomography (nanoCT) followed by 
processing for histology and immunohistochemistry (IHC). 
All animal procedures were approved by the local ethical 
committee for Animal Research (KU Leuven). The animals 
were housed according to the guidelines of the Animalium 
Leuven (KU Leuven).
Quantification of de novo formed bone by nanoCT
For 3D analysis of in vivo formed bone, explants were 
analysed using the Phoenix NanoTom S nanoCT system, 
(GE Measurement and Control Solutions, Wunstorf, DE) 
with a 180 kV/15 W high-performance nanofocus X-ray 
tube as previously described (Kerckhofs et al., 2013). 
Briefly, the system was equipped with a tungsten target 
and was operated at a voltage of 60 kV and a current of 
200 µA. A 1 mm aluminium filter was used to reduce beam 
hardening. The exposure time was 500 ms and a frame 
averaging of 1 and image skip of 0 were applied. CTAn 
software was used for 3D quantification (Bruker micro-CT, 
Kontich, BE), which employed a three-level automatic 
Otsu segmentation algorithm on the individual 2D slice 
where de novo formed bone and the CaP-grains could be 
segmented from the background. As a result, grey-scale 
images with distinct grey scale values for the bone, the 
CaP-grains and the background were generated for the 
different subsets. Percentage of bone was calculated with 
respect to the total explant volume.
Qualitative analysis of constructs in vivo performance
After nanoCT scanning, the samples were decalcified in 
0.5 M EDTA/PBS for 2 weeks, paraffin embedded and 
processed for qualitative assessment.
Histology
To analyse bone and bone marrow formation, haematoxylin 
and eosin (H&E) staining was performed. Briefly, paraffin 
sections were deparaffinised and subsequently immersed 
in haematoxylin (Sigma-Aldrich), rinsed in H2O followed 
by immersion in eosin (Klinipath, Duiven, NL). Finally, 
the sections were rinsed in H2O, dried in ethanol, cleared 
in Histoclear and mounted in PerTex mounting medium 
(CellPath, Wales, UK). Presence of cartilaginous matrix 
was investigated by toluidine blue staining. Sections 
were deparaffinised and subsequently immersed in 1 % 
toluidine blue (Merck). Next, sections were rinsed twice 
with isopropanol, cleared in xylene and mounted in PerTex. 
Bone remodelling was investigated by tartrate resistant acid 
phosphatase (TRAP) staining, performed to localise the 
presence of osteoclasts. Sections were deparaffinised and 
rehydrated through alcohols to PBS. Subsequently, sections 
were incubated with TRAP buffer containing 0.1 M acetate 
buffer, 0.3 M sodium tartrate and 1 % Triton X-100. The 
sections were then incubated in TRAP stain containing 
naphthol AS-MX phosphate (Sigma-Aldrich) and fast red 
violet LB (Sigma-Aldrich) in TRAP buffer at 37 °C. Each 
sample was counterstained in haematoxylin for 10 s and 
mounted with aqueous mounting medium.
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Immunohistochemistry
IHC for human OCN was performed on deparaffinised 
sections which were quenched in 3 % H2O2 followed by 
antigen retrieval in sodium citrate, 10 mM, pH 6, at 98 °C. 
Sections were then incubated in primary antibody for 24 h 
at 4 °C using a primary anti-OCN guinea pig antibody at 
a 1:1000 dilution (a generous gift from Dr. E. Van Herck, 
Legendo, KU Leuven) which does not cross-react with 
mouse OCN (De Bari et al., 2006). A HRP-conjugated anti 
guinea pig secondary antibody was used at a dilution of 
1:500 (Jackson) and 3,3’-diaminobenzidine (DAB, Sigma-
Aldrich) were used as a chromogenic substrate.
Histomorphometry
For semi-quantitative analysis, stained tissue sections 
were imaged for an overview or at four defined locations 
per section and used as a representative. ImageJ software 
was used for bone marrow quantification and scanned 
images from 3 sections per explant were utilised for 
an average value. The colour threshold was adjusted to 
depict the areas that display the positive areas by defining 
minimum and maximum values for each colour and an 
in-house developed MatLab code was used to quantify 
the positive area normalised to the total area. For positive 
OCN staining, images were blindly analysed and scored.
Statistical analysis
Data are expressed as individual data points with bars 
representing the average value. Statistical significance 
was determined using a non-paired unequal variance 
student t-test to compare between independent groups. 
Statistical significance is indicated on all graphs as follows; 
statistical significance to untreated control: #:p < 0.05, ##: 
p < 0.01, ###: p < 0.001; between conditions: *:p < 0.05, 
**: p < 0.01, ***: p < 0.001 (n = 3 for in vitro data and 
n = 4 for in vivo data). Principal component analysis 
(PCA) and hierarchical clustering using Ward’s method 
were performed in JMP® 10 (SAS Institute Inc., Cary, NC).
Fig. 1. hPDC characterisation and BMP-responsiveness. FACS analysis displayed 2D expanded hPDCs 93 % 
positive for MSC markers CD73, CD90 and CD105 (a). mRNA transcript analysis in 2D expanded hPDCs confirmed 
expression of BMP type 1 and type 2 receptors (b). Expression of BMP-receptors on protein level (green) with DAPI 
as nuclear stain (blue) in hPDCs (c). Functional antibody was confirmed in a prostate cancer cell line (PC3) (c). 
Monolayer cultures of hPDCs were stimulated with different BMP-ligands for 6 d. Bright field images displayed 
morphological differences between cells stimulated with different BMP-ligands (d). mRNA transcript analysis after 
6 d of stimulation displayed varied elevated expression of chondrogenic (e-f), osteogenic (g-h) and BMP-signalling 
(i-j) markers. Statistical significance by student t-test to untreated cells: *p < 0.05, **p < 0.01, ***p < 0.01 (n = 3). 
Unlabelled scale bar: 20 µm.
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Results
Characterisation of hPDCs’ responsiveness to BMPs
In vitro 2D expanded hPDCs were analysed for their 
MSC phenotype by flow cytometry and displayed 98.9 % 
positivity for CD73, CD90 and CD105 whereas 93 % 
were detected negative for haematopoietic markers CD14, 
CD20, CD34 and CD45, Fig. 1a. Next, mRNA transcripts 
for BMP type1 and type2 receptors (ALK1, ALK2, ALK3 
and ALK6 as well as BMPR2, ACVR2a and ACVR2b) 
were detected, Fig. 1b. On protein level, expression of 
ALK3, ALK6 and BMPR2 was confirmed but not ALK2, 
Fig. 1c. Functional antibody was confirmed in a prostate 
cancer cell line (PC3). After 6 d of 2D stimulation in the 
presence of BMP-2, -4, -6, -7, -9 or GDF5, bright field 
images displayed differences in cell morphologies upon 
incubation with the different ligands, Fig. 1d. Culture in the 
presence of BMP-2, -6 and -7 induced a more confluent and 
elongated culture whereas a BMP-4, -9 and GDF5 treatment 
resulted in a round cell shape. The early chondrogenic 
marker SOX9 displayed a 2-fold upregulation in hPDCs 
when stimulated with BMP-2, BMP-4, BMP-6, BMP-7 
and BMP-9 as compared to non-stimulated cells, Fig. 1e. 
ACAN, the main proteoglycan in cartilage matrix, hence a 
marker for chondrogenic differentiation, displayed a 20-, 
10- and 5-fold elevated expression upon BMP-2, BMP-4 
and BMP-9 stimulation, respectively, Fig. 1f. Analysis 
of the early osteogenic marker RUNX2 demonstrated an 
increased expression in all BMP-stimulated cells, Fig. 1g. 
A 10-fold elevation was observed by BMP-2, BMP-4 and 
BMP-9. Elevated OSX expression was induced by BMP-
2, BMP-4, BMP-7 and BMP-9, Fig. 1h. To see whether 
the enhanced differentiation was associated with activated 
BMP-signalling, expression of the BMP-target gene ID1 
and the transcriptional regulator DLX5 were investigated. 
In parallel to enhanced chondrogenesis and osteogenesis, 
a 10- and 2-fold upregulation of DLX5 and ID1 expression 
were detected when cultured in the presence of BMP-2, 
BMP-4 and BMP-9, Fig. 1i and 1j, respectively.
Ca2+ and BMP-2 release from BioOss® and CopiOs® 
scaffolds
As a first step, Ca2+-release was measured from the scaffolds 
during a 6-day period. A 3-fold higher burst release within 
24 h was observed in the CopiOs® scaffold as compared to 
BioOss®, Fig. 2a. The high release level of CopiOs® was 
maintained during the investigated period. However, in 
the BioOss® scaffold the level increased significantly on 
day 3 and 6 as compared to the first 24 h. Consistent with 
Ca2+ release, BMP-2 coated CopiOs® displayed a 3-fold 
higher burst release of BMP-2 after 24 h as compared to 
BioOss® scaffold, Fig. 2b. Cell seeding did not affect the 
BMP-2 release.
In vitro cell metabolism on CaP scaffolds
Based on gene expression analysis on 2D differentiated 
cells, BMP-2, BMP-4, BMP-6 and BMP-9 were further 
selected for coating of BioOss® and CopiOs® followed 
by cell seeding for 3D stimulation. Cell metabolism was 
investigated by measuring the ratio of lactate production 
to glucose consumption in conditioned media, Fig. 2c. 
Proliferating cells mainly use an aerobic fermentation 
process, where one glucose molecule results in two 
molecules of lactate. Hence, a ratio that differs from 
two may indicate that cells have adapted the metabolic 
pathway due to initiation of differentiation (e.g. oxidative 
phosphorylation (osteogenic differentiation) or altered 
anaerobic glycolysis (chondrogenic differentiation)). Cells 
seeded on non- or BMP-9 coated CopiOs® scaffolds and 
BMP-2 coated BioOss® displayed a ratio of 2 or above. 
Fig. 2. Ca2+ and BMP-2 release from CaP scaffolds and cellular response. To characterise material properties of the 
BioOss® and CopiOs® scaffolds, Ca2+ release was measured for 6 d (a). Scaffolds were then coated with the most 
potent BMP-ligands in inducing 2D differentiation and subsequently cell seeded. BMP-2 release was measured in 
BMP-2 coated scaffolds seeded with or without cells (b). Cell metabolism was investigated through Lactate: Glucose 
production and consumption 24 h post cell seeding (c). At the same time point, protein phosphorylation for downstream 
BMP-signalling was investigated through Western blot for the canonical BMP-pathway; Smad1/5/8 (d) and the non-
canonical MAPK pathways; p38 (e), MEK1/2 (f) and Erk1/2 (g). Statistical significance by student t-test, n = 3, to: 
uncoated scaffolds: #p < 0.05, ##p < 0.01, ###p < 0.01, between conditions: *p < 0.05, **p < 0.01, ***p < 0.01.
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Significantly lower ratios were seen in CopiOs® coated 
with BMP-2, BMP-4 and BMP-6, as compared to non-
coated scaffold.
In vitro BMP-pathway activation on CaP scaffolds
Next, protein lysates were prepared from the constructs 24 h 
post cell seeding for analysis of protein phosphorylation 
by Western blot. Canonical BMP-signalling (pSmad1/5/8) 
as well as non-canonical (pp38, pMEK1/2 and pErk1/2) 
downstream BMP-signalling were investigated. A 4- and 
5-fold increased level of pSmad1/5/8 was seen in BMP-2 
coated CopiOs® and BioOss®, respectively, as compared 
to non-coated scaffolds, Fig. 2d. Phosphorylation of p38 
displayed over a 2-fold increased level in BMP-2 and BMP-
6 coated scaffolds as compared to non-coated controls, 
Fig. 2e. MEK1/2 analysis displayed a 1.5- and 2.5- fold 
elevated phosphorylation in BMP-6 coated CopiOs® and 
BioOss® whereas BMP-2 and BMP-4 coated BioOss® 
showed 1.5- and 2.5-fold elevated levels, Fig. 2f. Erk1/2 
function downstream of MEK1/2 and a 1.5-fold higher 
phosphorylation level was seen in both BMP-4 and BMP-6 
coated BioOss®, Fig. 2g.
BMP-and CaP-induced bone formation
To investigate the in vivo performance, constructs were 
implanted in an ectopic nude mouse model for 5 weeks. 
Analysis of reconstructed 3D images from nanoCT scans 
displayed various tissue formation profiles by the different 
constructs, Fig. 3a. Upon quantification, BMP-2 and BMP-
6 coated scaffolds induced approximately 3 and 5 mm3 of 
de novo bone, respectively, Fig. 3b. Smaller volumes were 
induced by BMP-4 and BMP-9 coated BioOss® (± 1 mm3). 
Since the size of the explants varied, the percentage of de 
novo formed bone was calculated, normalised to the total 
explant volume, Fig. 3c. The highest percentage were 
observed in BMP-2 coated scaffolds with 14- and 10 % 
for CopiOs® and BioOss®, respectively.
Bone ossicle formation by BMP-2 and BMP-6
Bone ossicle formation was seen in CaP scaffolds coated 
with BMP-2 and BMP-6, Fig. 4a. These ossicles contained 
three distinct zones where the peripheral zone displayed a 
cortex-like structure, a middle zone containing trabeculae-
like structures and a centre zone where remnants of CaP-
granules together with trabeculae-like structures were 
Fig. 3. Quantification of BMP-induced bone formation. BMP-coated and cell seeded BioOss® and CopiOs® scaffolds 
were subcutaneously implanted in NMRInu/nu mice for 5 weeks. Explants were scanned by nanoCT for 3D visualisation 
(a) and total bone quantification (b). Since total explant volume varied between the different constructs, total bone 
percentage was calculated normalised to explant volume (c). Statistical significance by student t-test, n = 3, to: 
uncoated scaffolds: #p < 0.05, ##p < 0.01, ###p < 0.01, between conditions: *p < 0.05, **p < 0.01, ***p < 0.01.
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Fig. 4. Ossicle formation by BMP-2 and BMP-6. Reconstructed nanoCT-images of BMP-2 (a) and BMP-6 (b) 
coated BioOss® and CopiOs® scaffolds displayed ossicle like structures with a peripheral zone containing a cortex-
like bone structure, a middle zone with trabeculae-like bone structures embedded in bone marrow and a centre zone 
with remaining CaP granules and trabeculae-like bone spicules. Upon quantification, most of the percentage of total 
bone in all constructs came from the cortex structure (c). Statistical significance by student t-test, n = 4; *p < 0.05, 
**p < 0.01, ***p < 0.01.
Fig. 5. Characterisation of BMP-induced bone and cartilage formation. Histological analysis of constructs harvested 5 
weeks post implantation displayed varied tissue formation between the constructs. H&E staining display bone (black 
arrows), bone marrow (white arrows) and fibrous tissue (green arrows) formation (CopiOs®: a, BioOss®: c). Toluidine 
blue staining depicts cartilage tissue with hypertrophic chondrocytes (red arrows) mainly in the central parts of the 
BMP-coated CopiOs® scaffolds (CopiOs®:b and BioOss®: d). Histomorphometry of bone marrow quantification 
normalised to explant area (e). Statistical significance by student t-test, n = 4, to: uncoated scaffolds: #p < 0.05, 
##p < 0.01, ###p < 0.01, between conditions: *p < 0.05, **p < 0.01, ***p < 0.01.
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found. To analyse the ratio of each typical structure, new 
regions of interest were defined. These contained the 
peripheral cortex-zone, the middle bone marrow zone and 
the centre zone containing the remaining CaP-granules, 
Fig. 4a and 4b. Upon quantification, the cortex-like 
structure confined most of the newly formed bone in all 
conditions and this was further enhanced in BMP-coated 
CopiOs® scaffolds as compared to BioOss®, Fig. 4c.
Characterisation of BMP-induced bone, cartilage 
and bone marrow formation
Qualitative tissue analysis was investigated by histology 
and IHC. Fig. 5a and 5c display H&E staining, which 
confirmed the nanoCT data, bone is indicated with black 
arrows. The intensity of the stain suggests the lighter areas 
to be less mature bone, as seen in CopiOs® scaffolds coated 
with BMP-4, BMP-6 and BMP-9 and more dense bone in 
BMP-2 coated scaffolds. Toluidine blue staining confirmed 
cartilage matrix in CopiOs® constructs coated with BMP-
2, -4, -6 and -9, mainly in the central parts of the explants 
(indicated by red arrows), Fig. 5b and 5d. Fibrous tissue 
could be found in all explants (green arrows) and bone 
marrow was present in BMP-2 and BMP-6 coated scaffolds 
in the zone between the cortex-like structure and the inner 
centre (white arrows), Fig. 5a and 5c. Histomorphometry 
showed that BMP-6 coated BioOss® and BMP-2 coated 
CopiOs® gave rise to the highest percentage of bone 
marrow with 6 % and 4 % respectively, Fig. 5e.
Further characterisation of BMP/hPDC based bone 
formation
In addition to bone, cartilage and bone marrow formation, 
the presence of osteoclasts was analysed by TRAP staining 
and the contribution to the newly formed bone by the 
implanted cells by IHC for human OCN. Areas positive 
for TRAP-staining were found in all samples where 
de novo bone was observed. TRAP-positive cells were 
mainly localised adjacent to the bone or surrounding the 
remaining CaP-granules in the BioOss® constructs, Fig. 
6a. Quantification of TRAP-positive area displayed that 
the BioOss® explants had the highest percentage of TRAP-
positive regions, Fig. 6b. Next, IHC for human OCN 
confirmed the contribution of implanted cells to de novo 
formed bone, depicted by the brown stain in cell nuclei and 
bone matrix in Fig. 6c. Quantification confirmed that not all 
cells and bone matrix stained positive, suggesting that part 
of the bone was host derived, Fig. 6d. In addition, BMP-
2 and BMP-6 samples which displayed a zonal division 
Fig. 6. Mechanism and functional analysis of BMP-induced bone formation. The newly formed bone was characterised 
for its function and contribution of the implanted cells. TRAP staining is a measure of osteoclast activity and remodelling 
and positive areas are depicted by red stain (a). Quantification of TRAP-positive area normalised to image area (b). 
Implanted cells contribution to the newly formed bone was investigated by IHC for human OCN, positive cell nuclei 
and bone matrix is depicted by brown stain (c). Quantification of OCN-positive cells (d) and in the different zones in 
BMP-2 and BMP-6 coated scaffolds (e), where PZ; peripheral zone, MZ; middle zone and CZ; centre zone. Statistical 
significance by student t-test, n = 4, to: *p < 0.05, **p < 0.01, ***p < 0.01.
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Fig. 7. Multivariate statistical analysis of the empirical data. Computational tools were used in the analysis of empirical 
data. Clustering of gene expression analysis in 2D stimulated cells with the in vivo readouts of BMP-coated CopiOs® 
(a) and BioOss® scaffolds (b). Clustering of 3D in vitro measurements from BMP-coated CopiOs® and BioOss® 
scaffolds to in vivo skeletal tissue formation (c). PCA analysis display 2 component separating factors related to in 
vivo bone formation (Component 1) and Ca2+-BMP interaction (Component 2) (d).
containing an peripheral cortex-like zone (PZ), a middle 
bone marrow zone (MZ) and a centre zone (CZ) containing 
remaining CaP-granules, displayed a clear difference in 
contribution, Fig. 6e. The PZ was mainly host-derived, 
some positive staining was detected in the MZ of the BMP-
2 coated-CopiOs®, whereas both scaffold types displayed 
positivity within the bone in the CZ.
Multivariate statistical analysis of the empirical data
A drawback in a large set of empirical data, with several 
factors known to play critical roles in the experimental 
outcome, is the lack of understanding their contribution 
and importance. Therefore, we applied multivariate 
statistical analysis as a tool to investigate the weighted 
value of the introduced factors. Hierarchical clustering 
allows identifying similarities between experimental 
conditions across the data set. The closer the resemblance 
in measurement profile between two conditions, the closer 
they will be clustered together. Two-way clustering bundles 
the experimental conditions based on the measurement 
profile and show which of the measurements have similar 
profiles across the experimental conditions. Hierarchical 
clustering of in vitro 2D stimulation measurements and 
the in vivo bone formation displayed clustering of OCN 
expression in 2D stimulated cells and in vivo formed 
bone, bone marrow and bone remodelling for CopiOs® 
and BioOss®, Fig. 7a and 7b respectively. In addition, 
in BMP-2 coated CopiOs®, clustering of elevated 
expression of chondrogenic marker ACAN and ID1 was 
found. Readouts on BMP-pathway activation in 3D and 
in vivo tissue formation displayed clustering of total 
bone volume and bone marrow formation, trabeculae and 
cortex formation, % total bone with phosphorylation of 
Smad1/5/8 and p38, Fig. 7c. Moreover, grouping between 
Ca2+- and BMP-2-release from the scaffold was depicted 
while TRAP-positivity was clustered with phosphorylation 
of MEK1/2 and Erk1/2. Cluster analysis of the different 
combinations of BMP-ligand and CaP scaffold displayed 
grouping of non-coated CopiOs® to BMP-4 and BMP-9-
coated scaffold. A similar phenomenon was seen for the 
BioOss® scaffold, showing a dominant stimulatory role 
of the biomaterial over BMP-ligand in these constructs. 
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In contrast, BMP-6 coated CaP scaffolds are clustered, 
demonstrating a dominant role for BMP-6 over the 
biomaterial. Interestingly, BMP-2 coated biomaterials were 
clustered next to the same BMP-6 coated one, presenting 
BMP-2 to be less dominant over the biomaterial than 
BMP-6, but more so than BMP-4 and BMP-9. Principal 
component analysis allows the visualisation of the 
maximum amount of information that is present within 
the entire dataset. A principal component represents the 
information contained within the data by choosing linear 
combinations of the measurements in such a way that the 
first principal component accounts for as much as possible 
for the variance available in the data set. The second 
component is chosen in the same way under the added 
constraint of being uncorrelated to the first component. 
Upon analysis, two clear components separating the 
different conditions as well as biological readouts related 
to in vivo bone (Component 1) and Ca2+-BMP-interaction 
(Component 2), Fig. 7d.
Discussion
Well characterised cell based ATMPs have recently come 
to attention to replace standard treatment options for 
non-healing long bone fractures. Current advances in the 
development of biologically functional bone grafts further 
improve our knowledge regarding the early phases of bone 
regeneration, enabling clinically relevant development 
of functional constructs. Previous reports displayed that 
Ca2+-induced bone formation by hPDCs is a process that 
requires activation of BMP and Wnt signalling (Eyckmans 
et al., 2010). Encouragingly, bone formation in these 
constructs is a biomimetic process, where progenitor cell 
condensation, bone marrow and bone formation can be 
detected, a suggested requirement for a successful clinical 
outcome (Lenas et al., 2009a; Lenas et al., 2009b; Roberts 
et al., 2011). However, the process is slow and limited 
amounts of skeletal tissue are developed. Subsequently, 
we hypothesised that we could further improve these 
constructs’ bone forming capacity by coating the scaffolds 
with recombinant BMP-ligands. By including these 
potent factors in a cell based-strategy, more physiological 
levels of BMPs could be used, hence overcoming current 
impediments while reaching a satisfactory outcome with 
clinical translation in mind.
 Initially, in vitro expanded hPDCs were characterised 
and confirmed positive for MSC markers and for 
expressing the BMP type 1 and type 2 receptors. This was 
encouraging, since it has been reported that in vitro 2D 
culture and expansion of mesenchymal progenitor cells 
reduce MSC characteristics as well as responsiveness 
to stimulation (Bara et al., 2014). Subsequently, BMPs 
known to bind to these receptors, with previously reported 
osteochondrogenic properties, were selected. BMP-2, 
BMP-4, BMP-6 and BMP-9 enhanced chondrogenic 
as well as osteogenic differentiation which could be 
correlated to elevated BMP-signalling. The dual osteo- and 
chondrogenic differentiation profiles may be explained by 
the heterogeneous pool of progenitor cells and fibroblasts 
hPDCs represent (Roberts et al., 2015). Potentially, 
depending on the progenitor cell’s spatial location in 
the periosteal layer, cells may be primed for a specific 
differentiation pathway. Neither BMP-7 nor GDF5 induced 
differentiation in the present setting. Since previous reports 
confirm both factors having osteo-chondrogenic potency in 
vitro and/or in vivo, this was an unexpected finding and may 
be due to the experimental setup and/or species specificity 
(Eyckmans and Luyten, 2006; Gruber et al., 2001).
 Potent BMPs were then coated onto clinically approved 
CaP-scaffolds followed by cell seeding. After 24 h, neither 
BMP-9 nor BMP-4 coated CopiOs® displayed enhanced 
phosphorylation in any of the markers of the investigated 
pathways, even though 2D stimulation enhanced both 
osteo- and chondrogenic differentiation. Possibly, the 
CaP-environment interferes with the activated BMP-
signalling, since CaP-stimulation of hPDCs can lead to 
cell proliferation and osteogenic differentiation, further 
supported by the metabolic analysis (Agathocleous and 
Harris, 2013; Chai et al., 2014). BMP signalling pathways 
are strictly regulated by cross-talks and feedback-
loops, controlled by co-factors and inhibitors resulting 
in a controlled bone forming process upon accurate 
pathway activation (Groppe et al., 2002; Zhang et al., 
2013). Therefore, inappropriate Ca2+-stimulation may 
inhibit activated signalling by the coated BMP-ligand. 
Consequently, CaP-scaffolds may function synergistically 
with specific BMP-ligands while in an inhibitory fashion 
with others. Alternatively, protein phosphorylation can 
take place within an hour or even minutes after stimulation 
has started and can fluctuate due to events involved 
during phosphorylation, such as receptor-ligand complex 
internalisation and recycling (Goldberg et al., 2002). 
Therefore, phosphorylation events might not be reflected 
in the selected time point but still take place, even though 
the use of pooled cells minimises the risk. Nevertheless, the 
time point chosen, 24 h post cell seeding reflects the final in 
vitro stage of the construct prior to implantation, providing 
important information of the implanted construct, at the 
time of implantation.
 Upon in vivo implantation, all constructs coated with 
BMPs induced bone. However, BMP-2 and BMP-6 coated 
scaffolds induced the highest amount and gave rise to 
bone-organ organisation (Scotti et al., 2013). Interestingly, 
the peripheral cortex was formed mainly by host cells. 
Possibly, this could be an effect of BMP-diffusion from the 
scaffold, supported by the BMP-2 release. The diffusion 
may attract and stimulate host cells to form the peripheral 
cortex like structure during a fast process, leading to the 
more mature bone (Wildemann et al., 2011). The bone 
formed in the centre zone is to a larger extent formed by 
implanted cells and especially in the CopiOs® constructs, 
displayed as less mature. This proposes that the combined 
action of BMP- and CaP-stimulation of hPDCs results in a 
slower bone forming process following the endochondral 
pathway.
 Due to the large and complex set of empirical data, 
multivariate statistical methods were used to gain further 
insight into the effects of stimulatory factors in the 
experimental design. Interestingly, clustering was found 
between total bone, percentage of: bone marrow, trabeculae, 
cortex and total bone to elevated phosphorylation levels 
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of Smad1/5/8 and p38. This suggests the importance of 
their activation in BMP/CaP induced bone formation as 
the major activated pathways during cell differentiation. 
Another cluster was found for BMP- and Ca2+-release, 
suggesting elevated Ca2+-release to cause a decrease in pH, 
providing a more soluble environment for the BMP (Hillger 
et al., 2005; Kamp et al., 1998). Alternatively, the release 
of Ca2+ may mediate the subsequent release and biological 
availability of BMPs bound to the CaP-granules through 
hydrogen/ionic/electrostatic/hydrophobic interactions 
(Wang et al., 2013).
 TRAP staining, an indicator of osteoclast activity, 
was computationally related to elevated phosphorylation 
levels of the MAPK-pathway MEK1/2 - Erk1/2. This 
pathway was previously reported essential in blood 
vessel recruitment (Nakatsu et al., 2003), proposing 
this pathway being important in remodelling of these 
constructs. Moreover, a scaffold-specific clustering 
of in vivo bone tissue formation to BMP-induced 2D 
differentiation was seen. Tissue formation in BMP-coated 
CopiOs® was statistically related to elevated expression 
of chondrogenic-, osteogenic- as well as activated BMP-
signalling markers. BioOss® constructs on the other hand, 
where no cartilage remnants were found, was also not 
clustered to chondrogenic markers. This suggests that the 
CopiOs® scaffold may provide a more suitable environment 
for induction of endochondral bone formation, due to the 
specific CaP-environment provided. This is of relevance 
for clinical translation, since fracture healing through a 
cartilage intermediate will reach stability faster, essential 
for successful healing.
 Lastly, the cluster analysis provided information of 
the weighted value of specific BMP-ligands and the CaP-
scaffold characteristics, with regard to the in vitro activated 
pathways as well as to the in vivo outcome. Both BMP-4 
and BMP-9 coated scaffolds were clustered to uncoated, 
suggesting the scaffold characteristics to be dominant 
over BMP-4 and BMP-9 ligands. On the other hand, 
analysis of BMP-6 coated CaP-scaffolds suggests BMP-6 
to overrule the stimulatory effect of the CaP-materials. 
Interestingly, BioOss® scaffolds coated with BMP-2 was 
clustered to BMP-6 coated BioOss® followed by BMP-2 
coated CopiOs®. These data suggest that BMP-2 interacts 
with the CaP-material to a higher extent than BMP-6 
on stimulation of hPDCs, further supported by the PCA 
analysis. This is further reflected by the varied contribution 
to in vivo bone formation by cells seeded on the two CaP 
scaffolds. Possibly, the BMP and CaP-material interaction 
with subsequent in vivo tissue formation could be due to 
differently activated downstream signalling mechanisms 
which are regulated by the expression profile of BMP-
receptors by hPDCs.
 It has been reported that BMP-2 binds preferentially 
and predominantly to ALK3 whereas BMP-6 primarily 
binds to ALK2 (Ebisawa et al., 1999; ten Dijke et al., 
1994). On gene expression level, ALK2 expression was 
detected in hPDCs, however we failed to confirm this on 
the protein level. Even though activated BMP-6 signalling 
may occur by binding to other receptors, this could cause 
the less impressive contribution of the implanted/ donor 
cells in BMP-6 constructs. Subsequently, unbound BMP-
ligand released from the coated scaffold or secreted by 
the stimulated cells leads to recruitment of cells, when 
available, from the host environment. This is of relevance 
as fast and proper incorporation into the host tissue is 
essential for the clinical outcome.
 Before clinical translation, further studies regarding 
the concentration of BMP-ligands, additional time points 
and cells isolated from individual donors are required. 
Nevertheless, these data provide important insights in the 
combined effect of BMP- and CaP-induced bone formation 
for skeletal regenerative medicine.
Conclusion
In this study, we have combined the stimulatory effects 
of BMPs and 3D CaP-scaffolds into cell-based ATMPs 
for bone tissue engineering. Different bone forming 
capacities of the constructs were observed depending 
on the specific combination of BMP-ligand and CaP-
scaffold. The synergistic effect of these two factors leads 
to functional skeletal tissue formation including a cartilage 
intermediate, bone as well as bone marrow formation and 
tissue remodelling. This study presents further evidence 
for the potential of ligands from the BMP family in the 
development of cell-based constructs for bone regenerative 
strategies.
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Discussion with Reviewers
R. Vicki: How do you envision using the information 
gained from multivariate analyses to design tissue-
engineering strategies?
Authors: One of the hurdles in understanding and 
evaluating the effect of stimulatory factors in a 3D system 
is the complexity and the potential size of the experimental 
dataset. To deal with these hurdles, multivariate analysis 
is an efficient methodology to identify positive and/or 
negative factors in the system. Furthermore, the use of 
computational evaluation of the empirical data is a possible 
means to gain in-depth knowledge on cell-biomaterial 
interactions in a cost- and time-effective manner. We intend 
to use this information in various ways. Information on 
what measurements are most predictive for this outcome 
will allow us to further investigate these pathways or 
these material characteristics. This will then serve as a 
starting point for more mechanistic experimental and/or 
modelling studies that will ultimately lead to improved 
tissue engineering designs and strategies.
R. Vicki: Do you believe the results are highly related to 
the use of hPDC, or would they be generalisable for other 
hMSC?
Authors: Periosteum derived cells represent a unique 
source of osteo-chondroprogenitor cells, shown crucial 
for successful fracture repair. In comparison to other 
MSCs such as bone marrow stromal cells or adipocyte-
derived stem cells, differences in cell morphology as well 
as proliferation and differentiation capacity have been 
reported. Therefore, the response demonstrated in the 
presented manuscript by hPDCs should not be seen as 
general for other MSCs. Nevertheless, a similar approach 
would be of interest in order to develop promising ATMPs 
based on alternative cell populations.
D. James: How much of a contribution to bone formation 
can be attributed to host versus donor cells?
Authors: Contribution of implanted cells to the newly 
formed bone was investigated by immunohistochemistry 
for human specific osteocalcin. About 20 % of the cells 
entrapped or lining the newly formed bone displayed 
positive staining in constructs containing BMPs. However, 
this can be seen as an underestimation, since bone forming 
cells of human origin, depending on the differentiation 
state, may or may not be positive for osteocalcin.
D. James: Are there underlying differences in the 
crystalline structures of BioOss® and CopiOs® that 
accounts for the differences in BMP interactions and release 
characteristics?
Authors: The crystalline structures of BioOss® versus 
CopiOs® are indeed different. CaP-granules in BioOss® are 
derived from bovine bone (hydroxyapatite) with a highly 
crystalline structure. In contrast, those present in CopiOs® 
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are synthetic dicalcium phosphate (CaHPO4). This firstly 
causes a different interaction between the BMP ligand and 
the two scaffolds. Secondly, the highly crystallised CaP-
granules in BioOss® are fairly stable and dissolve slowly 
whereas the amorphous CaHPO4 in CopiOs
® dissolves 
relatively fast. Consequently, the release kinetics of 
BMP-ligands are affected due to the difference in material 
degradation attributed to the different crystalline structures.
Editor’s Note: Scientific Editor in charge of the paper: 
Joost de Bruijn.
